Recent Updates
Recently added Catalysts

Brainstorm Cell Therapeutics Inc.

BCLIFDA catalysts, PDUFA dates & pipeline intelligence
$0.79
▼ -0.02 · -3.53%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BCLI financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.7252W HIGH $6.00
Volume
9.62 K
Value Traded
7.42 K
Short % Float
6.06%
Days to Cover
1.5
-6.77%Week
-6.4%1 Month
+44.44%3 Month
-40.91%6 Month
-99.44%5 Year
-75.52%All Time

Cash Data

Unlock BCLI cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
11.51 M
EPS (TTM)
-1.98
P/E Ratio
-
Ent. Value
11.64 M
Total Shares
9.84 M
Float Shares
7.64 M
Insiders
22.32%
Institutions
10.40%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every BCLI catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BCLI Catalyst Timeline

Dated clinical, regulatory and corporate events for Brainstorm Cell Therapeutics Inc.

Unlock the full BCLI catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BCLI actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all BCLI historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
NurOwn Monoclonal antibodyNCT01051882Amyotrophic Lateral SclerosisPhase 3 COMPLETED 470Mar 1, 2013
Unlock the BCLI pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BCLI program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
NurOwn
Fast TrackOrphan
ALSPhase 3b2025-07-08participants survived more than five years from ALS symptom onset; the median survival in the group was 6.8 yearsRead MoreFDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment EffectivenessRead More
Scroll for more · summaries link to the source press release
Unlock every BCLI trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BCLI insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Lebovits ChaimOfficer (President & CEO)Buy 1,836 80,960 held$3.43 10/01/2024
Unlock the full BCLI insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in BCLI

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0 % 13.66 K 6.02 K -93.33% ( -84.23 K)
Unlock every fund holding BCLI
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BCLI
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BCLI ownership
Insider and institutional ownership, quarter by quarter.

BCLI Short Interest

Shares sold short, counted twice a month.

6.06%
Short % of Float
of tradable shares sold short
34.2K
Shares Sold Short
-6.1% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
23.4K
Avg Daily Volume
the average used for days to cover
Unlock BCLI short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BCLI option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BCLI option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BCLI options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BCLI ranks across every disease it competes in

Competitive Position is a premium feature
See how BCLI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BCLI News

About Brainstorm Cell Therapeutics Inc.

brainstorm-cell.com
Headquarters1325 Avenue of Americas
Founded07-10-2003
BIOPHARMAWATCH ELITE PLUS
Trade the next BCLI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime